Clone:
REA232
Type of antibody:
Primary antibodies, Recombinant antibodies
Isotype:
recombinant human IgG1
Applications:
FC, MICS, IF, IHC, ICC, MC
Alternative names:
CXCR3, CD183, CKR-L2, CMKAR3, GPR9, IP10-R, Mig-R, MigR

Extended validation for CD183 (CXCR3) Antibody, anti-human, REAfinity™

Specificity

Epitope competition
In order to compare the epitope specificity of an antibody, the clone being used is compared with other known clones recognizing the same antigen in a competition assay.
Other clonesOverlap in epitope recognition with REA232
1C6/CXCR3++
CEW33D++
G025H7++
Cells were incubated with an excess of purified unconjugated CD183 (CXCR3) (REA232) antibody followed by staining with fluorochrome-conjugated antibodies of other known clones against the same marker. Based on the fluorescence signal obtained, the clones were identified as recognizing completely overlapping (++), partially overlapping (+), or completely different epitopes (-) of the marker.

Sensitivity

Performance comparison
Selected fluorochrome conjugated antibodies from Miltenyi Biotec were compared to commercially available hybridoma clones in flow cytometry analysis.
View details
Flow cytometric comparison of different clones for CD183 (CXCR3). Human peripheral blood mononuclear cells (PBMCs) were stained with CD183 (CXCR3) antibodies and with a suitable counterstaining. As a control, CD183 (CXCR3) antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.
View details
Flow cytometric comparison of different clones for CD183 (CXCR3). Human peripheral blood mononuclear cells (PBMCs) were stained with CD183 (CXCR3) antibodies and with a suitable counterstaining. As a control, CD183 (CXCR3) antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.
View details
Flow cytometric comparison of different clones for CD183 (CXCR3). Human peripheral blood mononuclear cells (PBMCs) were stained with CD183 (CXCR3) antibodies and with a suitable counterstaining. As a control, CD183 (CXCR3) antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.
View details
Flow cytometric comparison of different clones for CD183 (CXCR3). Human peripheral blood mononuclear cells (PBMCs) were stained with CD183 (CXCR3) antibodies and with a suitable counterstaining. As a control, CD183 (CXCR3) antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.
View details
Flow cytometric comparison of different clones for CD183 (CXCR3). Human peripheral blood mononuclear cells (PBMCs) were stained with CD183 (CXCR3) antibodies and with a suitable counterstaining. As a control, CD183 (CXCR3) antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.
Flow cytometric comparison of different clones for CD183 (CXCR3). Human peripheral blood mononuclear cells (PBMCs) were stained with CD183 (CXCR3) antibodies and with a suitable counterstaining. As a control, CD183 (CXCR3) antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.
Fixation data
To provide an indication on how an antibody performs after fixation of cells, in-house data on staining results before and after fixation with 3.7% formaldehyde using Miltenyi Biotec antibodies are provided. Different experimental settings may lead to different results.
No fixation
Post fixation
View details
Comparison of staining pattern on non-fixed and fixed cells using CD183 (CXCR3) (REA232). The performance of the antibody after fixation was tested by comparing the staining pattern on fresh (no fixation) versus fixed (post fixation) cells.
View details
Comparison of staining pattern on non-fixed and fixed cells using CD183 (CXCR3) (REA232). The performance of the antibody after fixation was tested by comparing the staining pattern on fresh (no fixation) versus fixed (post fixation) cells.
Comparison of staining pattern on non-fixed and fixed cells using CD183 (CXCR3) (REA232). The performance of the antibody after fixation was tested by comparing the staining pattern on fresh (no fixation) versus fixed (post fixation) cells.

Specifications for CD183 (CXCR3) Antibody, anti-human, REAfinity™

Overview

Clone REA232 recognizes CD183, a 38 kDa G protein–coupled chemokine receptor. CD183 harbors seven-transmembrane α-helices, an extracellular N-terminal domain containing three loops involved in the chemokine ligand binding, an intracellular C-terminal domain involved in signal transduction. CD183 binds CXCL9, CXCL10, and CXCL11 as ligands. CD183-ligand interactions play role in diverse cellular functions such as chemotactic migration, cell proliferation, and death. Expression of CD183 is found on T cells, human airway epithelial cells, NK cells, plasmacytoid dendritic cells, mast cells, alveolar macrophages, and eosinophils.
Additional information: Clone REA232 displays negligible binding to Fc receptors.

Alternative names

CXCR3, CD183, CKR-L2, CMKAR3, GPR9, IP10-R, Mig-R, MigR

Detailed product information

Technical specifications

CloneREA232
Clonalitymonoclonal
Isotyperecombinant human IgG1
Isotype controlREA Control Antibody (S), human IgG1
Hostcell line
Type of antibodyPrimary antibodies, Recombinant antibodies
Specieshuman
AntigenCD183 (CXCR3)
Alternative names of antigenCXCR3, CD183, CKR-L2, CMKAR3, GPR9, IP10-R, Mig-R, MigR
Distribution of antigenT cells, NK cells, epithelial cells, mast cells, T cells, NK cells, mast cells, epithelial cells
RRIDAB_2734058, AB_2751636, AB_2751590, AB_2752156, AB_2752105, AB_2811347, AB_2811334, AB_2784025, AB_2784024, AB_2784023, AB_2784022, AB_2655743, AB_2734057

References for CD183 (CXCR3) Antibody, anti-human, REAfinity™

Publications

  1. Hu, J. K. et al. (2011) Expression of chemokine receptor CXCR3 on T cells affects the balance between effector and memory CD8 T-cell generation. Proc. Natl. Acad. Sci. U.S.A. 108: E118-E127
  2. Colvin, R. A. et al. (2004) Intracellular domains of CXCR3 that mediate CXCL9, CXCL10, and CXCL11 function. J. Biol. Chem. 279: 30219-30227
  3. Bergmann-Leitner, E. et al. (2018) Identification of immune signatures of novel adjuvant formulations using machine learning. Sci Rep 8(1): 17508
  4. Farooq, F. et al. (2016) Circulating follicular T helper cells and cytokine profile in humans following vaccination with the rVSV-ZEBOV Ebola vaccine. Sci Rep 6: 27944

Related products for
CD183 (CXCR3) Antibody, anti-human, REAfinity™

3 products available